CYBNCYBIN INC.

NYSE cybin.com


$ 0.25 $ 0.00 (-1.93 %)    

Thursday, 27-Jun-2024 10:40:44 EDT
QQQ $ 481.94 $ 1.96 (0.41 %)
DIA $ 392.16 $ 1.37 (0.35 %)
SPY $ 546.57 $ 1.08 (0.2 %)
TLT $ 93.57 $ 0.14 (0.16 %)
GLD $ 215.20 $ 0.49 (0.23 %)
$ 0.2642
$ 0.26
$ 0.25 x 200
$ 0.00 x 0
$ 0.25 - $ 0.26
$ 0.25 - $ 0.74
5,456,515
na
200.81M
$ 0.49
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 biopharma-co-cybin-reports-78m-loss-amid-accelerating-expansion-in-psychedelic-therapies-drug-development

Explore Cybin Inc.'s FY 2024 results: $78M loss and strides in psychedelic therapy for mental health. Read now!

 cantor-fitzgerald-reiterates-overweight-on-cybin

Cantor Fitzgerald analyst Charles Duncan reiterates Cybin (AMEX:CYBN) with a Overweight.

 latest-executive-cannabis-changes-you-should-know-about-curaleaf-planet-13-elect-directors-and-more

As the premier gathering of top entrepreneurs and investors is taking place this Monday in New Jersey, let's scroll through...

Core News & Articles

https://www.marijuanamoment.net/oregons-first-in-nation-psilocybin-industry-is-struggling-to-find-paying-customers-a-year-after...

 psychedelic-stocks-trip-up-after-fda-advisors-reject-mdma-for-ptsd-treatment

FDA panel rejects MDMA therapy for PTSD, citing lack of evidence for benefits outweighing risks. Psychedelic stocks take a hit,...

 hc-wainwright--co-reiterates-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.

Core News & Articles

https://www.marijuanamoment.net/fda-expert-committee-will-review-mdma-assisted-therapy-for-ptsd-next-month/The Food and Drug Ad...

 cybin-provides-corporate-update-and-highlights-upcoming-clinical-milestones-initiation-of-pivotal-cyb003-phase-3-study-in-mdd-expected-in-mid-2024-phase-2-topline-efficacy-and-safety-results-for-cyb004-in-generalized-anxiety-disorder-expected-q4-2024

- Recent U.S. $150 Million funding round lead by a syndicate of leading biopharmaceutical institutional investors supports adva...

Core News & Articles

https://www.marijuanamoment.net/indiana-lawmakers-send-psilocybin-research-funding-bill-to-governor/   The Indiana legislatur...

 cybin-announces-end-of-phase-2-meeting-with-fda-for-cyb003-in-major-depressive-disorder-and-phase-3-program-design

Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company co...

 hc-wainwright--co-maintains-buy-on-cybin-maintains-5-price-target

HC Wainwright & Co. analyst Patrick Trucchio maintains Cybin (AMEX:CYBN) with a Buy and maintains $5 price target.